NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141
NN9490-8293
Phase 3 small_molecule active
Quick answer
NNC0487-0111 B 10146, NNC0487-0111 B 10143, NNC0487-0111 B 10142, NNC0487-0111 B 10145, Placebo, NNC0487-0111 B 10144, NNC0487-0111 B 10141 for Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP) is a Phase 3 program (small_molecule) at Novo Nordisk A/S with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Novo Nordisk A/S
- Indication
- Overweight or obesity, and obstructive sleep apnoea treated with positive airway preassure (PAP)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active